Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Glaucoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Glaucoma
    Silent Cerebral Infarcts a Risk Factor for Visual Field Loss in Patients With Normal-Tension Glaucoma - (DGNews)
    Dosing Aid Provides Accurate Snapshot of Travoprost Compliance in Patients With Primary Open-Angle Glaucoma: Presented at COS - (DGDispatch)
    Buccal Membrane Is Effective in Repair of Leaking Trabeculectomy Blebs, Exposed Glaucoma Drainage Devices: Presented at COS - (DGDispatch)
    TopAbstracts in Glaucoma 06/29/2009 - (DGNews)
    Antiglaucoma Medications Do Not Adversely or Favourably Affect Selective Laser Trabeculoplasty Success: Presented at COS - (DGDispatch)

    News archive

     Recent webcasts/CME - Glaucoma
      Managing Ocular Surface Disease in the Glaucoma Patient
      Adjunctive Medical Therapy: New Evidence and Treatment Strategies for Glaucoma
      Enhancing Adherence with Glaucoma Therapy: Practical Strategies for Superior Outcomes

      Webcasts/CME archive

       Recent cases - Glaucoma
        Topiramate-Associated Acute Glaucoma in a Migraine Patient Receiving Concomitant Citalopram Therapy: A Case-Report
        Central Retinal Artery Occlusion and Non-Arteritic Anterior Ischemic Optic Neuropathy Associated with an Overlap Syndrome: A Case Report
        Argon Laser Peripheral Iridoplasty for Plateau Iris Associated with Iridociliary Cysts: A Case Report
        Missed Case of Axenfeld-Rieger Syndrome: A Case Report
        Good Functional Recovery Following Intervention for Delayed Suprachoroidal Haemorrhage Post Bleb Needling: A Case Report

        Cases archive
          




        my personal edition > glaucoma > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Brimonidine-Purite Comparable to Brimonidine Alone in Lowering Intraocular Pressure

        A DGReview of :"Twelve-Month Evaluation of Brimonidine-Purite Versus Brimonidine in Patients With Glaucoma or Ocular Hypertension"
        Journal of Glaucoma

        04/26/2002
        By Mark Moran


        Brimonidine-purite 0.15% and 0.2%, appears to decrease intraocular pressure comparably to brimonidine 0.2% in patients with glaucoma or ocular hypertension.

        Jay Katz, MD, of the Brimonidine-Purite Study Group, Wills Eye Hospital, Philadelphia, Pennsylvania, United States headed this 12-month, randomized, multi-center study of the two drugs--with brimonidine-Purite tested at two different concentrations. The group found that brimonidine-Purite 0.15% showed the most favorable safety and tolerability profile and a reduced incidence of allergic conjunctivitis. It also showed a better satisfaction and comfort rating.

        There were no statistically significant differences in mean intraocular pressure or mean changes from baseline intraocular pressure (at peak or trough) among groups receiving either drug. Difference in mean intraocular pressure between patients receiving brimonidine-purite-0.15% and those receiving brimonidine-0.2% treatment group was less than 1 mmHg.

        The relative percent difference in allergic conjunctivitis was 41% lower in the brimonidine-purite 0.15% group compared with the brimonidine 0.2% group. The comfort and satisfaction rating significantly favored brimonidine-Purite 0.15%, he reports.

        In the study, 381 patients were randomly assigned to receive brimonidine-Purite 0.15%, 383 received brimonidine-Purite 0.2%, and 383 received brimonidine 0.2%. All patients received the drugs three times daily, and mean intraocular pressure at baseline was similar in the three treatment groups.

        Diurnal intraocular pressure was measured four times daily at baseline, week six, and at three months, six months, and 12 months. Intraocular pressure was also measured twice daily at week two and month nine. Safety was evaluated by adverse events and other ocular and systemic measures.
        J Glaucoma 2002 April;11(2):119-126. "Twelve-Month Evaluation of Brimonidine-Purite Versus Brimonidine in Patients With Glaucoma or Ocular Hypertension"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send